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The in vivo validation of cancer mutations and genes identified in cancer genomics is resource-intensive because of
the low throughput of animal experiments. We describe a mouse model that allows multiple cancer mutations to
be validated in each animal line. Animal lines are generated with multiple candidate cancer mutations using
transposons. The candidate cancer genes are tagged and randomly expressed in somatic cells, allowing easy
identification of the cancer genes involved in the generated tumours. This system presents a useful,
generalised and efficient means for animal validation of cancer genes.Background
The sequencing of cancer genomes has become a globally
coordinated effort to understand the genomic, epigenetic
and gene expression changes that occur in cancers [1]. By
coupling the output of the catalogues of mutations and al-
terations in cancer genomes with systematic functional
analyses, an overarching aim is to derive both an under-
standing of the underlying pathophysiological process and
improved clinical outcomes [2-4]. The functional valid-
ation and characterisation of candidate cancer mutations
presents a practical challenge in cancer genomics, due to
the diversity of assays and in particular the costs and dur-
ation of in vivo experiments.
DNA transposons are mobile genetic elements that
translocate within the genome via a ‘cut-and-paste’ mech-
anism. They are versatile genetic tools used in a variety of
genetic models for purposes ranging from transgene de-
livery to mutagenesis and chromosome engineering
[5,6]. The Sleeping Beauty (SB) transposon is active in
mammalian cells and has been used for cancer gene
discovery in a variety of tissue contexts by insertional
mutagenesis [7-10]. The piggyBac (PB) transposon is a
DNA transposon recently described to be active in mouse
ES cells with much higher transposition efficiency than* Correspondence: pl2@sanger.ac.uk; afutreal@mdanderson.org
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unless otherwise stated.Sleeping Beauty [11,12]. We have previously shown that
enhancer/transcript-trapping DNA transposons targeted
into the genome can be used to assay the in vivo oncogenic
potential of the payload cDNA contained in the transposon
[13]. Tumourigenesis in this system requires the conflu-
ence of appropriate genetic, temporal and microenvir-
onment contexts: first, the transposon must carry an
oncogenic cDNA; second it traps a transcript that ex-
presses the cDNA at an appropriate level; third, this oc-
curs in a susceptible tissue and at a proper developmental
stage; and finally, the cDNA confers a selective advantage
so that expression is maintained by positive selection. A
bacterial artificial chromosome vector constructed to
carry an array of transposons with different cDNAs was
targeted to the Hprt locus using recombination mediated
cassette exchange in ES cells. When animals generated
from these ES cells were crossed to a strain ubiquitously
expressing transposase, the progeny developed a broad
spectrum of tumours that expressed the oncogenic
cDNAs but not the control cDNAs from the transposon
array. The transposons stochastically mobilise in som-
atic cells, expressing their payload cDNA when they in-
sert near enhancers or expressed genes and trap the
expression activity. Due to the ubiquitous expression of
transposase, transposons can also remobilise and lose
payload cDNA expression. Therefore, the expression of
an individual or group of transposon cDNA(s) clonally
maintained within an expanding tumour over time wouldtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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approach effectively assays the oncogenic potential of each
cDNA payload in multiple tissue contexts. As transposition
is somatic and cell-autonomous, each somatic cell would
have a unique transposon insertion profile and a single ani-
mal line with a library of transposons could develop tumours
driven by different combinations of oncogenic cDNAs.
To practically use transposon-mediated in vivo tumouri-
genesis to functionally validate cancer mutations, we re-
quired an efficient method for transfecting transposons
into the murine genome and a strategy for tracking the
transposons. To address those needs, we describe here a
nested PB-SB transposon vector that allows pools of mul-
tiple transposons to efficiently transduce into the genome
of mouse embryonic stem (ES) cells [12]. Individual trans-
posons constructs are tagged with unique 3’ UTR se-
quences to track the exogenous cDNAs and facilitate
genotyping. We used this system to assay the in vivo
oncogenic potential of a set of kinase mutations we have
previously observed in human cancers [14], recovering
tumours that recurrently expressed a subset of the
cDNAs. The tumours show selective retention of certain
cDNAs during serial transplantations and generation
cell lines. Exome sequencing of the tumours revealed
intratumour heterogeneity and evolutionary life histor-
ies similar to that observed in human cancers. In two
examples of mutations in Cyclin-dependent kinase 2
(CDK2) and Diacylglycerol kinase, beta (DGKB) genes,
we show how the in vivo assay reveals novel insights on
the functions of these genes in cancer. This system uses
standard molecular biology and transgenic protocols,
yielding a general mouse model for validating cancer
mutations in a wild-type background that is polygenic
in throughput. This in vivo validation system comple-
ments and informs in vitro cell-based assays in func-
tional cancer genomics.
Results and discussion
Design and generation of transposon constructs
To transfect pools of transposons into the genome of
cells without constructing or manipulating large arrays
of transposons in bacterial artificial chromosome con-
structs that were required previously [13], we rationalised
that we could take advantage of the high transposition ef-
ficiency of piggyBac that is two to three orders of magni-
tude higher than the Sleeping Beauty transposon in ES
cells [12]. By nesting the rest of the transposon vector de-
sign within PB terminal repeats (Figure 1a), we can effi-
ciently introduce pools of cargo payload within the PB
repeats into the genome of cells by co-electroporating
transposon constructs with a helper plasmid encoding PB
transposase. The nested PB and SB transposon design
(Figure 1a) permits us to use either PB or SB transposase
to mobilise the transposon in vivo. As our intention wasto assay the oncogenic potential of the cDNA payload
itself and not the oncogenic potential from disruption
of an endogenous loci or novel fusion transcripts, we in-
troduced an internal ribosomal entry sequence (IRES)
after the splice acceptor sequence so that the cDNA
payload is expressed alone. We incorporated a 60-
basepair unique sequence tag between the stop codon
and poly-A signal (Figure 1a and see Additional file 1:
Table S1). This tag allows us to specifically detect the
presence of the transposon in the genome and expres-
sion of the cDNA transcript by PCR, and eliminates
possible non-specific amplification from the endogen-
ous gene.
To evaluate the efficiency of the pooled electroporation
strategy, we combined a pool of 24 unique sequence-tagged
PB transposons constructs with the transposase helper
plasmid for electroporation into mouse ES cells. Co-
electroportation led to a genomic distribution of unique
transposon insertions where approximately 20% of 73
genotyped Neomycin-resistant clones have greater than
six unique transposons using PCR genotyping of the se-
quence tags (Figure 1b). This frequency distribution
demonstrates the utility of pooled transposon electropor-
ation and suggests that the probability of each transposon
integrating is independent of the other constructs.
For the candidate cDNA payloads, we curated a list of 18
kinase mutations from a variety of cancers [14] (Figure 1c),
chosen for their likelihood to function as dominant gain-
of-function point mutations based either on the location
of the mutation in the functional domains or the distribu-
tion of mutations within the gene. In addition to the
mutant alleles, we also constructed transposons with
the 11 wild-type cDNA sequences to compare the ef-
fects of ectopic expression of the kinases.
Generation of animals for tumourigenesis assay
The schematic illustrating animal generation for in vivo
tumourigenesis is outlined in Figure 1d. We electropo-
rated pools of six to 25 transposon constructs together
with the piggyBac transposase helper plasmid into AB2.2
and JM8A3 mouse ES cell lines [15,16]. Different repre-
sentations of transposons were identified in the electropo-
rated ES cell clones by PCR genotyping using primers
specific to each cDNA and its corresponding unique se-
quence tag (Figure 1a and Additional file 1: Table S1). We
used ES cell clones that each carried four to 21 unique
transposons to generate chimaera animals by blastocyst
microinjection (Additional file 1: Table S2). The pools
were combinations of mutations in different genes, and
a pool of different mutations in the same gene (DGKB).
Potential passenger effects due to insertional mutagen-
esis by the transposon are avoided by having multiple
animal lines generated from different ES cell clones
with different pools and initial insertion profiles, so that
Figure 1 Transposon mediated in vivo validation of cancer mutations. (a) Schematic for design of transposon construct, not to scale. Arrows
show relative primer positions for subsequent genotyping and PCR assays. ATG, translation start codon of incorporated cDNA; IRES,
encephalomyocarditis virus internal ribosome entry site; pA, bovine growth hormone poly-adenylation signal; PB, piggyBac; SA, Engrailed splice
acceptor; SB, Sleeping Beauty; TR, terminal repeat. (b) Distribution of unique transposon species in pooled electroporation. A pool of 24 unique
sequence-tagged transposons containing the neomycin resistance marker is electroporated into murine ES cells and colonies selected for in
media supplemented with geneticin. Distribution shown is for 73 picked clones that are geneticin-resistant. (c) List of kinase mutations and the
tumour type where they were observed in human patients. For each kinase both the wild-type and mutant versions of the cDNA were
constructed and incorporated into individually tagged transposon constructs. (d) Schematic of the experimental strategy for in vivo validation of
candidate cancer gene alleles using transposon. (e) Genotyping PCR with forward primer in cDNA and reverse primer in sequence tag (see panel
a) to detect presence of individual transposons. Each row shows an individual animal with the 25 PCR reactions to the different transposons, 3 F1
progeny from a litter are shown. (f) In F1 pups with SB transposase, both intact transposon (detected by the junction primers) and SB mobilisation
(detected by the flanking primers) are detectable (primers shown in Figure 1a). Loss of the nested SB transposon results in the PCR reaction
amplifying a product of similar size to the terminal repeat junctions.
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covered from different tumours would have originated
from cells with distinct initial transposon integration sites(Additional file 1: Table S2). In parallel, we electroporated
transposon pools into ES cell lines already expressing ei-
ther the PB or SB transposase, the chimaeras generated
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can be used directly for the tumourigenesis assay in the F0
generation chimaeras. To provide a sensitised background
for tumourigenesis, we also co-electroporated a subset of
ES cells with a transposon constitutively expressing the
dominant-negative R270H allele of the Trp53 tumour
suppressor gene [17] under the control of the CAGG
(cytomegalovirus early enhancer and chicken beta-actin
promoter hybrid) synthetic promoter.
Chimaera animals with pools of transposons in their
genome were subsequently crossed to a mouse line ex-
pressing the SB11 transposase from the ubiquitous
Rosa26 promoter [10]. In the F1 progeny of this cross,
we are able to detect individual transposons in genomic
DNA using primers designed to amplify the cDNA and
its unique sequence tag (Figure 1e). While Mendelian
segregation of the different transposon insertions in the
F1 progeny is expected given the random integration of
transposons into the genome, we observed that individ-
uals in the cohort of three littermates shown have simi-
lar representations of the transposon pool, this is likely
due to multiple copies of each individual transposon be-
ing present in the genome at different loci. We are able
to verify that the nested transposon is intact, and where
SB11 transposase was used to mobilise the transposon,
we can also verify the excision of the SB transposon
from the flanking PB terminal repeats by PCR (Figure 1f).
Validating cancer mutations by tumourigenesis in vivo
For in vivo tumourigenesis, we aged the mice with daily
health monitoring for malignancy. As detailed in Table 1,
chimaeric mice with both transposons and transposase
expression presented histopathology-verified tumours at
a higher rate than control mice that had transposons but
no constitutive transposase expression (details of individ-
ual animals in Additional file 1: Table S2). In F1 progeny
animals, the presence of a transposon expressing the dom-
inant negative allele of p53 reduced the median tumour
latency by 33.5 weeks; interestingly, these had lower inci-
dence of tumours. This might be due to a lower general
fitness in animals with this transposon, resulting in
more animals being culled for non-malignancies. Given
that transposon mobilisation is a cell independent somatic
event and individual transposons are also represented in
different pool combination and ES cell clones, we scored
the occurrence of each candidate cDNA expression inTable 1 Summary of in vivo tumourigenesis assay
Generation Transposase Transposons Animals (n) Animals with tum
F0 chimaeras + + 21 8
F0 chimaeras - + 20 3
F1 animals + + 65 44
F1 animals + + (p53.R270H) 20 6different tumour types as a way to assess the potential of a
given cDNA in contributing to tumourigenesis. We de-
tected cDNA expression from the transposons in approxi-
mately half of the tumours assayed. In tumours without
detectable cDNA expression, we are not able to distin-
guish between tumours that arose because of a transient
effect of an oncogene (for example, the expression of a
mutant kinase cDNA from a transposon might have con-
tributed to the establishment of a clone but is then lost
subsequently), versus tumours that arose due to other mu-
tations occurring spontaneously. While the potential for
remobilisation is an inevitable effect of the constitutive
transposase activity, we reasoned that we should avoid any
a priori assumptions on the suitable developmental stage
or timing for mobilisation of the transposons. Also, the
ability to incorporate in vivo selection pressure to retain
transposon expression would provide a more stringent
assay for validating the candidate cDNAs, while decreas-
ing the potential passenger transposon insertions that
might occur after a transient transposase mobilisation.
Table 2 shows the occurrence for expression of each
transposon in each tumour type.
Each occurrence of a cDNA’s expression in a tumour
represents a potential context in which its expression
contributed to tumourigenesis. In tumours, we often see
loss of transposons and transposon cDNA expression
compared to normal untransformed tissues. This bias
can arise from clonal competition in dividing tumour
cells, as transformed cells are likely to be represented by
a few successful subclones. In contrast, the mixture of
clones within normal tissues with different transposon
insertion and expression profiles results in a net repre-
sentation of most transposons from the germline. As an
example, in an F0 PB transposase expressing chimaera
(animal id PLKD4.1a) with hepatocellular carcinoma
(Figure 2a and b), the expression pattern in normal tis-
sues suggests that stochastic and ectopic expression of
many kinase alleles can be tolerated in normal tissues. In
the tumour, only a subset of kinase transposon and
cDNA expression is positively selected for and retained
(Figure 2b).
To examine whether tumours retain transposon pay-
load expression and have serial engraftment capacity,
we transplanted fragments of 23 primary tumours by sub-
cutaneous injection into immune-compromised NOD.Cg-
Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice [18]. We observedours (n) Median tumour latency (weeks) Animals with tumours (%)
85.5 38
89.9 15
108.4 67
74.9 30
Table 2 Occurrence of transposon cDNA expression in
different tumour types
cDNA Lymphoma Carcinoma Blastoma Sarcoma Total
CDK2.P45L 11 5 0 0 16
ERN1.S768F 8 4 0 0 12
LYN 5 6 0 0 22
ERN1 6 4 0 0 10
ITK 6 3 0 0 9
MAPK8.G171S 5 4 0 0 9
NTRK3 3 6 0 0 9
HCK.D378G 4 4 0 0 8
MAPK8 4 4 0 0 8
CDK2 4 3 0 0 7
MAPK8.G177R 3 4 0 0 7
MGC42105.P411T 5 2 0 0 7
DGKB 4 1 1 0 6
HCK 2 4 0 0 6
NTRK3.H677Y 4 2 0 0 6
YSK4 4 2 0 0 6
YSK4.E512V 3 2 0 0 5
MAPK9 3 1 0 0 4
MGC42105 3 1 0 0 4
ITK.P23L 2 1 0 0 0
NTRK3.R678Q 1 2 0 1 1
DGKB.D592Y 0 0 0 1 1
DGKB.G501S 0 0 0 1 1
DGKB.P432S 0 0 0 1 1
MAPK9.K56N 0 1 0 0 1
DGKB.K704E 0 0 0 0 0
DGKB.M111I 0 0 0 0 0
LYN.D385Y 0 0 0 0 0
MAPK9.V13M 0 0 0 0 0
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NSG mice. Of the five engrafted tumours, we attempted
serial transplantation and four engrafted successfully again
in NSG mice. In addition, efforts to create tumour cell
lines from 34 primary tumours led to 13 tumour cell lines
(38% success rate). As an example, from an F1 animal (id
PLKH1.4b) with lymphoma, the tumour engrafted in NSG
mice serially and maintained consistent histopathological
features (Figure 2c). This animal had no transposon cDNA
expression in sampled normal tissues and only CDK2.
P45L expression in the lymphoma, the expression of the
transposon cDNA was maintained through the serial
transplants and also in cell lines derived from the tumour
and the secondary engraftment (Figure 2d). Of the four
tumours that underwent two serial engraftments, threeshowed retention of the transposon cDNA expression ob-
served in the primary tumours.
The transposon construct with expression detected
most frequently in tumours was the mutant allele of
Cyclin-dependent kinase 2 (CDK2.P45L, Table 1). The
CDK2.P45L-expressing tumours were from animals gen-
erated by six independent ES cell clones with different
pools of transposon insertions, pointing to the recur-
rence of CDK2.P45L expression as a result of positive
selection. The CDK2.P45L mutation is a point substitu-
tion we observed once in a single glioblastoma patient
where the conserved proline residue in the PSTAIRE
interaction motif is replaced with leucine [14]. The
PSTAIRE motif is the central helical motif in the inter-
action of CDK2 with its regulatory partner CYCLIN E1.
Biochemical assays suggest that CDK2.P45L is unlikely
to drive oncogenesis through an activating gain of func-
tion or deregulation mechanism, as the mutation dis-
rupts the interaction between CDK2 and its regulatory
binding partner CYCLIN E1 even though its kinase ac-
tivity is retained [19]. Nevertheless, the recurrence and
selective retention of expression in tumours (Figure 2a-d)
observed here suggests that it can contribute a positive
selective advantage to tumours in vivo.
In a separate pool, six transposons with alleles of DGKB
(5 mutants, 1 wild-type) were introduced into the ge-
nomes of the ES cells, these mutations were observed in
lung and melanoma cancer genomes (Figure 1c). The
wild-type, K704E and P432S alleles have varying activity
in transforming Ink/Arf-null mouse embryonic fibro-
blast (MEF) cells when expressed together with HRAS.
V12 (Figure 2e). This transformation activity does not
correlate with kinase activity of the protein, as the
M111L allele retains kinase activity but does not co-
operate with HRAS.V12 in transformation (Figure 2f ).
Remarkably, only the expression of the wild-type DGKB
cDNA was recurrently recovered in multiple tumours
(Table 1). While both substrate and product of DGKB
(diacylglycerol and phosphatidic acid, respectively) play
diverse roles in intracellular signalling [20], our data
suggest that overexpressed DGKB can have oncogenic
activity that is unrelated to its kinase activity, possibly
through a scaffold or complex recruitment function
given that the substitution mutants do not appear to
contribute to tumourigenesis in vivo in this experimen-
tal context.
Bi-functional transposons designed with strong promoter/
enhancer elements to drive ectopic gene expression and
splice-acceptor-polyA signals to disrupt expression have
been successfully used as insertional mutagens to iden-
tify cancer genes [7-10]. Unlike the insertional mutagen-
esis transposons used in those screens, the design of our
cDNA delivery transposon does not contain any pro-
moter/enhancer elements. While there is a possibility
Figure 2 Tumours generated in animals with transposons. (a) An F0 chimaera (animal id PLKD4.1a) that presented with hepatocellular
carcinoma in two liver lobes (m1 and m2), histological sections from both tumours visualised with haemotoxylin and eosin (H&E) stains. (b)
Transposon expression (RT-PCR using cDNA) and representation (PCR using genomic DNA (gDNA)) in two tumour samples and normal lung. (c)
An F1 animal (id PLKH1.4b) that presented with a solid lymphoma tumour (top panel), H&E histological section. Serial subcutaneous transplants of
the tumour in NSG mice gave rise to secondary (middle panel) and tertiary tumours (lower panel). (d) Transposon expression of PLKH1.4b in the
serially transplanted tumour, cell lines derived from the primary and secondary transplanted tumours, and normal kidney tissues. (e) Colony
forming assay of different DGKB alleles in cooperation with HRAS.V12 using Ink/Arf mutant MEFs. MYC is a positive control. Error bars denote
standard deviation, P value from two-tailed T-test compared to HRAS.V12 alone. (f) Relative activity of different DGKB alleles as measured by
phosphatidic acid (PA) production. (g) Number of mutated genes unique to and shared between two regions of a single lymphoma that was
exome-sequenced. Known cancer genes with mutations are shown.
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can disrupt the expression of an endogenous tumour sup-
pressor gene locus in a particular tumour sample, possibly
resulting in hypomorphic gene function, the complete dis-
ruption of any particular gene function in a cell requires
either a disrupting insertion followed by spontaneous loss
of heterozygosity at the other copy, or two independent
disrupting insertions at both copies of the gene in the
chromosome pair. The basis of validating a candidate
cDNA payload is based on observing recurrent expression
across tumours from different animals, different founderanimals derived from multiple ES cell clones, and with
each tumour having a unique somatic profile of trans-
poson insertions. Nevertheless, to assess whether the
transposon-mediated delivery of the cDNAs contributes
to a potential mutational load and to understand the co-
operating mutations that could act together with the
expressed exogenous kinases to drive tumourigenesis,
we performed paired-end exome sequencing on tumour
and normal matched samples from two animals that
presented with lymphoma (animal ids PLKB4.1b and
PLKE5.1a). Variants were called using customised CaVEMan
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methods). To validate the variants, we used Sanger se-
quencing for indels and pyrosequencing for substitu-
tions. We validated 125 somatic mutations in PLKB4.1b
and 28 somatic mutations in PLKE5.1a (Additional file 1:
Tables S3, S4). Both animals were F0 chimaeras generated
from transposase expressing ES cells, PB transposase in
PLKB4.1b and SB transposase in PLKE5.1a. As PB trans-
position has been described to be largely precise and
error-free in multiple species with no defined molecular
signature [6,12,21,22], we are unable to quantify the rela-
tive contribution of transposon activity in the generation
of the additional mutations in PLKB4.1b. However, given
that SB excision results in a characteristic insertion of a
short motif comprising the end of the transposon terminal
repeat and a duplication of the TA dinucleotide insertion
site [23,24], it is possible to estimate if transposition repre-
sents a significant mutation load. From the PLKE5.1a
exome, none of the validated mutations exhibit the mo-
lecular footprint arising from SB transposition, suggesting
that other additional drivers of mutations in tumours do
occur and play the major role in the generation of these
additional mutations. As the PLKB4.1b tumour was
macroscopically heterogeneous, we sampled two different
regions of the tumour for exome sequencing (sample ids
PLKB4.1b3 and PLKB4.1b4). The two regions had 70
common mutations (75% and 68% of each region’s muta-
tions respectively) that included five of the six known can-
cer genes mutated in both regions (Figure 2g, [25]). Both
regions express CDK2.P45L cDNA. The regional exome
sequencing shows that while a core set of mutations is
likely to have contributed to the tumour, intra-tumour
heterogeneity and genotypic divergence occurred in the
life history of the tumour.
The CDK2 and DGKB mutations highlight as examples
that in vivo validation can provide novel information on
the oncogenic activity of mutant alleles that would not be
gleaned from biochemical or cell biology assays alone. In
the case of CDK2.P45L, even though the mutant is unable
to form a stable association with its cognate activating
cyclin [19], the in vivo data showing positive selection for
the expression of the mutant cDNA suggest that there
could potentially be additional assembly factors that facili-
tate transient association between CDK2 and CYCLIN E1.
For the DGKB mutant alleles, the uncoupling of kinase
activity, transformation activity and in vivo representation
in tumours underscores the critical importance for the
multiplicity and depth of validation assays in functional
cancer genomics. Without complementary functional
characterization with in vitro and cell-based assays for the
other mutations listed in Figure 1c, we are intentionally
cautious in refraining from asserting whether the other
mutations are validated or non-functional passenger mu-
tations in the cancer genome. Even so, we note that ourdata presented here can serve to direct future investiga-
tions. Expression of both the wild-type and S768F mutant
allele of endoplasmic reticulum to nucleus signalling 1
(ERN1, also IRE1) are the second and fourth most fre-
quently recovered transposon cDNAs in our study
(Table 2), corroborating recent description of ERN1 as
playing key roles in tumour angiogenesis, growth and
invasion [26,27]. In contrast, for the v-yes-1 Yamaguchi
sarcoma viral related oncogene homologue (LYN) kin-
ase that is implicated in a wide variety of cancers
[28-30], while expression of the wild-type kinase is the
third most frequent occurrence, we never recovered
any tumours expressing the D385Y mutant (Table 2).
This would suggest that the D385Y mutation is poten-
tially a loss-of-function mutation, though this has to be
characterised molecularly with biochemical and cell-
based activity assays.
In this study, lymphomas and carcinomas were the pre-
dominant types of tumours generated. While the CDK2.
P45L mutation was originally discovered in glioblastoma
multiforme, its corresponding cDNA expression was de-
tected in 11 lymphomas and five carcinomas in the in vivo
tumourigenesis assay. This probably reflects a susceptibil-
ity of tissues to transformation and the underlying pro-
pensities of the promoter-transposase and transposon
species combinations used here. A similar predisposition
towards haematopoietic malignancies was observed in the
first whole-body insertional mutagenesis screens with the
SB transposon [7,8], and the predisposition can be varied
by using a different transposon such as PB or by express-
ing the transposase from different promoters [31]. Indeed,
from our relatively small cohort of F0 chimaeras derived
from ES cells expressing transposase, a single SB100
transposase-expressing animal presented with lymphoma.
In comparison, six animals derived from ES cell clones ex-
pressing the PB transposase presented with lymphomas,
hepatocellular carcinomas and a Wilms-like blastoma. Fu-
ture iterations of this validation system could incorporate
tissue-specific promoters or conditional ‘Lox-stop-Lox’ cas-
settes in the transposon to facilitate granular control for
validating candidate cancer mutations in a tissue, develop-
mental and temporal-specific manner.
With a larger animal cohort and tumour numbers, it
also would be informative to explore in further studies
whether co-expression of multiple transposon cDNA
payloads could be indicative of synergistic genetic inter-
actions in the pool. In this study, we have not taken into
account the presence of any other transposon cDNA ex-
pression when looking at the recurrence of individual
candidate cDNA payload, including the expression of
the dominant-negative Trp53 in some of our pools. We
reasoned that it should be the selective retention of
cDNA expression that is an indication of a candidate’s
contribution to clonal selection and oncogenic potential.
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the exogenous kinase cDNAs, the exome sequencing of
the tumours show that these bona fide tumours can have
additional mutations that are either prevalent or divergent
within the tumour, exhibiting intratumour genotypic di-
versity and heterogeneity similar to that observed in the
clonal evolutionary history of human tumours [32,33].
Conclusions
We have shown here an efficient in vivo system for valid-
ating cancer genes that uses standard molecular biology
and transgenic techniques. Several systems for elegant for-
ward and reverse genetic screens have been engineered in
mice that look at genes in specific tumour tissue types
(that is, liver or brain) or in specific cancer processes such
as metastasis [34-38]. While those systems allow for spe-
cific studies in particular tumour types and biological pro-
cesses, the system described here allows for generalised
whole-body in vivo validation of gain of function or
neomorphic alleles that are observed in human cancer
genomes. Given the crucial importance of balancing the
requirements of in vivo validation with the resource-
intensive nature of animal experiments, the system de-
scribed here is advantageous as a generalised in vivo
validation step in functional cancer genomics. The
identification or validation of genes in vivo should be
complemented by molecular and cellular characterisa-
tion. With our collection of kinase mutations that have
not been previously characterised in vivo, we show here
for the P45L mutation in CDK2 and the DGKB alleles
that in vivo contexts can reveal phenotypic divergences
and nuances when compared to standard cell-based or
biochemical assays. Compared to our previous experi-
mental system that required the construction of large
bacterial artificial chromosomes for the transposon
gene arrays [13], the procedures for generating these
animals are relatively simple, providing an easy means
of polygenic validation in multiple somatic tissue types
per animal line that is not previously accessible. This
transposon-based in vivo system allows us to isolate
somatic tumours where the oncogene candidates are
expressed in a susceptible tissue microenvironment and
at levels that are clonally advantageous, complementing
existing in vitro and cell-based assays for validating and
characterising genes. By using a system where the candi-
date mutation has to be selectively retained, this system
also provides a means of generating cell lines useful for
further characterising functional requirements and roles
of the mutations. This is particularly advantageous as
cancer genes and mutation candidates from large scale se-
quencing studies are often not preserved within a func-
tional context in patient-derived cell lines. While the
overall throughput of validation described here averages a
little less than a dozen candidate cDNAs per animal line,the relative simplicity of the techniques described here is
scalable with the number of candidates for validation by
increasing the number of animal lines. The in vivo valid-
ation system described here should prove to be a useful
addition to the current suite of functional cancer genom-
ics tools.
Materials and methods
Transposon constructs
The piggyBac transposase construct and components of
the nested PB-SB transposon vector were cloned as pre-
viously described [12,13]. Kinase mutations were gener-
ated using the QuikChange Lightning Site-Directed
Mutagenesis Kit (Stratagene) and cDNA clones from the
IMAGE consortium. NTRK3 cDNA was a gift from B.D.
Nelkin [39]. The cDNAs and the 60-basepair unique se-
quence tag were added by PCR cloning (KOD, Takara)
into the transposon vector (See Additional file 1: Table S1
for tag sequences).
Cell culture
Both AB2.2 and JM8A3 mouse ES cells were grown in
standard M15 media on SNL76/7 feeder cells [40]. M15
comprises Knockout DMEM (GIBCO), 15% Fetal Bovine
Serum (Invitrogen), 1× Pencillin, Streptomycin and Glu-
tamine (GIBCO), 1× Non-Essential Amino Acids (GIBCO),
0.1 mM β-mercaptoethanol (Sigma), 1,000 U/mL human
LIF (Millipore). Tumour derived cell lines were cultured
in RPMI with 10% Fetal Bovine Serum (Invitrogen), 1×
Pencillin, Streptomycin and Glutamine (GIBCO), 1× Non-
Essential Amino Acids (GIBCO).
Manipulation of mouse ES cells
To electroporate mouse ES cells, cells were harvested
by trypsinisation, washed in PBS and resuspended to
107 cells/mL. For each mL of cells, 30 μg total of
pooled transposon constructs of equal quantity were
co-electroporated with 10 μg of CAGG-PBase transposase
helper plasmid and 30 ng of PB-SB-pGK-Neo co-selection
marker on a Biorad GenePulser. The electroporation
settings are 230 V, 500 μF with expected time constant
between 5.6 and 8.0. In all transposon pools, PB-SB-
ires-eGFP is a negative control in the pool. Selection for
clones containing transposon using PB-SB-pGK-Neo co-
selection was done in M15 media supplemented with
125 μg/mL Geneticin (GIBCO).
Animal work
All animal-related protocols and care was provided in
accordance with the Animal (Scientific Procedures) Act
1986. To generate animals, chimaera animals were gener-
ated by injecting ES cells into blastocysts as per standard
protocols. For the tumourigenesis assay, animals are
aged and monitored daily for signs of malignancy. Animals
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exposure to rising CO2 concentration, followed by necropsy
and histolopathological analyses of tissues.
For serial tumour transplant, tumour samples were har-
vested immediately after the animal was culled. Tumour
tissue is briefly surface sterilised in 70% ethanol and imme-
diately washed in PBS, followed by mincing with scalpels.
Fine tumour mince is injected subcutaneously into the
flanks of NSG mice with a 21-gauge needle and syringe.
Histology
Tissues were fixed overnight in 10% formalin (Sigma),
dehydrated and cleared for paraffin embedment as per
standard histology protocols. The paraffin blocks were
cut at 5 μm thickness and stained with haematoxylin
and eosin as per standard protocols. All culled animals
were scored for presence of tumour and tumour type(s)
as applicable, independently of the detection of trans-
poson and cDNA expression without randomisation or
blinding.
Detecting transposon and payload cDNA expression
Both genomic DNA and RNA are isolated from cells or
tissues using an AllPrep kit (Qiagen) where fresh tissues
were available, this was not done in cases such as found
dead animals where the tissues were degraded. For re-
verse transcriptase reaction, cDNA was synthesised from
extracted RNA using Superscript III (Invitrogen). PCR
was done on standard conditions using Extensor (Thermo),
primers pairs are listed in Additional file 1: Table S5. The
primer pair for Transferrin receptor (Tfrc) positive control
spans an intron, allowing detection of any genomic DNA
contamination in cDNA PCR and vice versa.
Cell line derivation
Fresh tumour mince is divided between three 35 mm tis-
sue culture dishes and incubated for 16 h in RPMI media
supplemented with 30, 100 and 300 U/mL collagenase II
(GIBCO). Cells from all three dishes are collected the next
day, centrifuged at 200 rcf for 5 min and washed in RPMI
media to remove the collagenase. The resulting cell sus-
pension is seeded into 75 cm2 flasks, media changed every
2 to 4 days until the cells are approximately 80% confluent
and ready for subculturing.
Kinase assay
DGKB kinase activity was assessed by measuring the
abundance of phosphatidic acid (PA) as a reflection of
cellular DGK activity in protein lysates, as described pre-
viously [41]. Briefly, lysates from 293 cells transfected
with the wild-type and indicated DGKB mutants were
separated by thin layer chromatography, PA abundance
was analysed by autoradiography. Empty vector andBacterial DGK were used as negative and positive con-
trols, respectively.Transformation assay
Ink4a/Arf-deficient primary murine embryonic fibroblasts
(MEFs) were plated in DMEM containing 10% FBS at a
density of 8 × 105 cells per 10 cm, 16 h before transfection.
For RAS cooperation, 1.5 μg HRAS(Val 12) vector was
co-transfected with 6.5 μg pEF-Dest51-LacZ control vec-
tor, MYC or the indicated DGKB variants in pEF-Dest51
using Lipofectamine2000 (Invitrogen) following the man-
ufacturer’s instructions. The total amount of transfected
DNA was kept constant at 7.5 μg, and transfections were
done in duplicate three times. At 48 h after transfection,
each transfected 10-cm plate was equally split into three
10-cm plates and incubated for 10 days, during which
media was refreshed twice. Cells were washed, fixed in
10% formalin and stained with Giemsa solution (Sigma)
for 10 min at room temperature for foci quantification.
Two-tailed t-test calculations were performed using Prism
4 (Graphpad).Exome sequencing
Sequencing was based on exome capture and performed
using 76 basepair paired-end reads on the Illumina GAIIx
platform. The sequencing data are deposited into the
European Nucleotide Archive under study accession num-
ber ERP000896. Mapping of the sequence data was done
using BWA [42]. Variant calling was done using CaVE-
Man (Cancer Variants through Expectation Maximisation)
[43] for substitutions and Pindel [44] for insertions and
deletions, modifications to the variant callers and subse-
quent filtering were as previously described [45]. These
algorithms identified somatic variants in the tumour
samples compared to matched normal sample for the
same animal.Additional file
Additional file 1: Table S1. Tag sequences. Table S2. Details of
tumour bearing mice. Table S3. Validated mutations from animal
PLKB4.1b. Table S4. Validated mutations from animal PLKE5.1a. Table S5.
Genotyping primers.Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
SKC, DL, LSC, JW and AC designed, performed and analysed results of the
transposon and animal experiments. KLS, AS and LC designed, performed
and analysed results of the in vitro characterisation experiments. SKC, KR, JH,
JWT, DJ, AM, APB and JG analysed the sequencing data with SO and SM
providing sample processing and technical support. SKC, PL and PAF wrote
the manuscript with discussion and input from all authors. PL and PAF
directed the research. All authors read and approved the final manuscript.
Chew et al. Genome Biology 2014, 15:455 Page 10 of 11
http://genomebiology.com/2014/15/9/455Acknowledgements
We thank the Wellcome Trust Sanger Institute’s Research Support Facility,
Mouse Genome Project, Histology and Sequencing teams for their technical
support; Dr BD Nelkin (Johns Hopkins Medicine) for the NTRK3 cDNA
plasmid. This work was supported by the Wellcome Trust.
Author details
1Wellcome Trust Sanger Institute, Hinxton, UK. 2Current address: UCL Cancer
Institute, London, UK. 3Current address: Babraham Institute, Cambridge, UK.
4Baylor College of Medicine, Houston, TX, USA. 5Novartis Institutes for
Biomedical Research, Cambridge, MA, USA. 6University of Texas MD
Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA.
Received: 10 March 2014 Accepted: 27 August 2014References
1. Hudson TJ, Anderson W, Artez A, Barker AD, Bell C, Bernabe RR, Bhan MK,
Calvo F, Eerola I, Gerhard DS, Guttmacher A, Guyer M, Hemsley FM,
Jennings JL, Kerr D, Klatt P, Kolar P, Kusada J, Lane DP, Laplace F, Youyong
L, Nettekoven G, Ozenberger B, Peterson J, Rao TS, Remacle J, Schafer AJ,
Shibata T, Stratton MR, Vockley JG, et al: International network of cancer
genome projects. Nature 2010, 464:993–998.
2. Boehm JS, Hahn WC: Towards systematic functional characterization of
cancer genomes. Nat Rev Genet 2011, 12:487–498.
3. Chin L, Gray JW: Translating insights from the cancer genome into
clinical practice. Nature 2008, 452:553–563.
4. Stratton MR, Campbell PJ, Futreal PA: The cancer genome. Nature 2009,
458:719–724.
5. Candela H, Hake S: The art and design of genetic screens: maize. Nat Rev
Genet 2008, 9:192–203.
6. Thibault ST, Singer MA, Miyazaki WY, Milash B, Dompe NA, Singh CM,
Buchholz R, Demsky M, Fawcett R, Francis-Lang HL, Ryner L, Cheung LM,
Chong A, Erickson C, Fisher WW, Greer K, Hartouni SR, Howie E, Jakkula L,
Joo D, Killpack K, Laufer A, Mazzotta J, Smith RD, Stevens LM, Stuber C,
Tan LR, Ventura R, Woo A, Zakrajsek I, et al: A complementary transposon
tool kit for Drosophila melanogaster using P and piggyBac. Nat Genet
2004, 36:283–287.
7. Collier LS, Carlson CM, Ravimohan S, Dupuy AJ, Largaespada DA: Cancer
gene discovery in solid tumours using transposon-based somatic
mutagenesis in the mouse. Nature 2005, 436:272–276.
8. Dupuy AJ, Akagi K, Largaespada DA, Copeland NG, Jenkins NA: Mammalian
mutagenesis using a highly mobile somatic Sleeping Beauty transposon
system. Nature 2005, 436:221–226.
9. Ivics Z, Hackett PB, Plasterk RH, Izsvak Z: Molecular reconstruction of
Sleeping Beauty, a Tc1-like transposon from fish, and its transposition in
human cells. Cell 1997, 91:501–510.
10. Starr TK, Allaei R, Silverstein KA, Staggs RA, Sarver AL, Bergemann TL, Gupta M,
O'Sullivan MG, Matise I, Dupuy AJ, Collier LS, Powers S, Oberg AL, Asmann YW,
Thibodeau SN, Tessarollo L, Copeland NG, Jenkins NA, Cormier RT,
Largaespada DA: A transposon-based genetic screen in mice identifies
genes altered in colorectal cancer. Science 2009, 323:1747–1750.
11. Ding S, Wu X, Li G, Han M, Zhuang Y, Xu T: Efficient transposition of the
piggyBac (PB) transposon in mammalian cells and mice. Cell 2005,
122:473–483.
12. Wang W, Lin C, Lu D, Ning Z, Cox T, Melvin D, Wang X, Bradley A, Liu P:
Chromosomal transposition of PiggyBac in mouse embryonic stem cells.
Proc Natl Acad Sci U S A 2008, 105:9290–9295.
13. Su Q, Prosser HM, Campos LS, Ortiz M, Nakamura T, Warren M, Dupuy AJ,
Jenkins NA, Copeland NG, Bradley A, Liu P: A DNA transposon-based
approach to validate oncogenic mutations in the mouse. Proc Natl Acad
Sci U S A 2008, 105:19904–19909.
14. Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G, Davies
H, Teague J, Butler A, Stevens C, Edkins S, O'Meara S, Vastrik I, Schmidt EE,
Avis T, Barthorpe S, Bhamra G, Buck G, Choudhury B, Clements J, Cole J,
Dicks E, Forbes S, Gray K, Halliday K, Harrison R, Hills K, Hinton J, Jenkinson
A, Jones D, et al: Patterns of somatic mutation in human cancer
genomes. Nature 2007, 446:153–158.
15. Bradley A, Zheng B, Liu P: Thirteen years of manipulating the mouse
genome: a personal history. Int J Dev Biol 1998, 42:943–950.16. Pettitt SJ, Liang Q, Rairdan XY, Moran JL, Prosser HM, Beier DR, Lloyd KC,
Bradley A, Skarnes WC: Agouti C57BL/6 N embryonic stem cells for mouse
genetic resources. Nat Methods 2009, 6:493–495.
17. Olive KP, Tuveson DA, Ruhe ZC, Yin B, Willis NA, Bronson RT, Crowley D,
Jacks T: Mutant p53 gain of function in two mouse models of
Li-Fraumeni syndrome. Cell 2004, 119:847–860.
18. Shultz LD, Lyons BL, Burzenski LM, Gott B, Chen X, Chaleff S, Kotb M, Gillies SD,
King M, Mangada J, Greiner DL, Handgretinger R: Human lymphoid and
myeloid cell development in NOD/LtSz-scid IL2R gamma null mice
engrafted with mobilized human hemopoietic stem cells. J Immunol
2005, 174:6477–6489.
19. Child ES, Hendrychova T, McCague K, Futreal A, Otyepka M, Mann DJ: A
cancer-derived mutation in the PSTAIRE helix of cyclin-dependent kinase
2 alters the stability of cyclin binding. Biochimica et biophysica acta 2010,
1803:858–864.
20. Caricasole A, Bettini E, Sala C, Roncarati R, Kobayashi N, Caldara F, Goto K,
Terstappen GC: Molecular cloning and characterization of the human
diacylglycerol kinase beta (DGKbeta) gene: alternative splicing generates
DGKbeta isotypes with different properties. J Biol Chem 2002,
277:4790–4796.
21. Fraser MJ, Ciszczon T, Elick T, Bauser C: Precise excision of TTAA-specific
lepidopteran transposons piggyBac (IFP2) and tagalong (TFP3) from the
baculovirus genome in cell lines from two species of Lepidoptera. Insect
Mol Biol 1996, 5:141–151.
22. Grossman GL, Rafferty CS, Fraser MJ, Benedict MQ: The piggyBac element
is capable of precise excision and transposition in cells and embryos
of the mosquito, Anopheles gambiae. Insect Biochem Mol Biol 2000,
30:909–914.
23. Plasterk RH, Izsvak Z, Ivics Z: Resident aliens: the Tc1/mariner superfamily
of transposable elements. Trends Genet 1999, 15:326–332.
24. Luo G, Ivics Z, Izsvak Z, Bradley A: Chromosomal transposition of a Tc1/
mariner-like element in mouse embryonic stem cells. Proc Natl Acad Sci
U S A 1998, 95:10769–10773.
25. The Cancer Gene Census [http://www.sanger.ac.uk/genetics/CGP/Census/]
26. Auf G, Jabouille A, Guerit S, Pineau R, Delugin M, Bouchecareilh M, Magnin N,
Favereaux A, Maitre M, Gaiser T, von Deimling A, Czabanka M, Vajkoczy P,
Chevet E, Bikfalvi A, Moenner M: Inositol-requiring enzyme 1alpha is a key
regulator of angiogenesis and invasion in malignant glioma. Proc Natl Acad
Sci U S A 2010, 107:15553–15558.
27. Drogat B, Auguste P, Nguyen DT, Bouchecareilh M, Pineau R, Nalbantoglu J,
Kaufman RJ, Chevet E, Bikfalvi A, Moenner M: IRE1 signaling is essential for
ischemia-induced vascular endothelial growth factor-A expression and
contributes to angiogenesis and tumor growth in vivo. Cancer Res 2007,
67:6700–6707.
28. Choi YL, Bocanegra M, Kwon MJ, Shin YK, Nam SJ, Yang JH, Kao J,
Godwin AK, Pollack JR: LYN is a mediator of epithelial-mesenchymal
transition and a target of dasatinib in breast cancer. Cancer Res 2010,
70:2296–2306.
29. Iqbal MS, Tsuyama N, Obata M, Ishikawa H: A novel signaling
pathway associated with Lyn, PI 3-kinase and Akt supports the
proliferation of myeloma cells. Biochem Biophys Res Commun 2010,
392:415–420.
30. Wheeler SE, Morariu EM, Bednash JS, Otte CG, Seethala RR, Chiosea SI,
Grandis JR: Lyn kinase mediates cell motility and tumor growth in
EGFRvIII-expressing head and neck cancer. Clin Cancer Res 2012,
18:2850–2860.
31. Rad R, Rad L, Wang W, Cadinanos J, Vassiliou G, Rice S, Campos LS,
Yusa K, Banerjee R, Li MA, de la Rosa J, Strong A, Lu D, Ellis P,
Conte N, Yang FT, Liu P, Bradley A: PiggyBac transposon
mutagenesis: a tool for cancer gene discovery in mice. Science
2010, 330:1104–1107.
32. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E,
Martinez P, Matthews N, Stewart A, Tarpey P, Varela I, Phillimore B, Begum S,
McDonald NQ, Butler A, Jones D, Raine K, Latimer C, Santos CR, Nohadani M,
Eklund AC, Spencer-Dene B, Clark G, Pickering L, Stamp G, Gore M, Szallasi Z,
Downward J, Futreal PA, Swanton C: Intratumor heterogeneity and branched
evolution revealed by multiregion sequencing. N Engl J Med 2012,
366:883–892.
33. Park SY, Gonen M, Kim HJ, Michor F, Polyak K: Cellular and genetic
diversity in the progression of in situ human breast carcinomas to an
invasive phenotype. J Clin Invest 2010, 120:636–644.
Chew et al. Genome Biology 2014, 15:455 Page 11 of 11
http://genomebiology.com/2014/15/9/45534. Bric A, Miething C, Bialucha CU, Scuoppo C, Zender L, Krasnitz A, Xuan Z,
Zuber J, Wigler M, Hicks J, McCombie RW, Hemann MT, Hannon GJ, Powers S,
Lowe SW: Functional identification of tumor-suppressor genes through an
in vivo RNA interference screen in a mouse lymphoma model. Cancer Cell
2009, 16:324–335.
35. Gumireddy K, Sun F, Klein-Szanto AJ, Gibbins JM, Gimotty PA, Saunders AJ,
Schultz PG, Huang Q: In vivo selection for metastasis promoting genes in
the mouse. Proc Natl Acad Sci U S A 2007, 104:6696–6701.
36. Wangensteen KJ, Wilber A, Keng VW, He Z, Matise I, Wangensteen L, Carson CM,
Chen Y, Steer CJ, McIvor RS, Largaespada DA, Wang X, Ekker SC: A facile method
for somatic, lifelong manipulation of multiple genes in the mouse liver.
Hepatology 2008, 47:1714–1724.
37. Wiesner SM, Decker SA, Larson JD, Ericson K, Forster C, Gallardo JL, Long C,
Demorest ZL, Zamora EA, Low WC, SantaCruz K, Largaespada DA, Ohlfest JR:
De novo induction of genetically engineered brain tumors in mice using
plasmid DNA. Cancer Res 2009, 69:431–439.
38. Zender L, Xue W, Zuber J, Semighini CP, Krasnitz A, Ma B, Zender P, Kubicka S,
Luk JM, Schirmacher P, McCombie WR, Wigler M, Hicks J, Hannon GJ, Powers S,
Lowe SW: An oncogenomics-based in vivo RNAi screen identifies tumor
suppressors in liver cancer. Cell 2008, 135:852–864.
39. McGregor LM, Baylin SB, Griffin CA, Hawkins AL, Nelkin BD: Molecular
cloning of the cDNA for human TrkC (NTRK3), chromosomal assignment,
and evidence for a splice variant. Genomics 1994, 22:267–272.
40. McMahon AP, Bradley A: The Wnt-1 (int-1) proto-oncogene is required
for development of a large region of the mouse brain. Cell 1990,
62:1073–1085.
41. Saci A, Carpenter CL: RhoA GTPase regulates B cell receptor signaling.
Mol Cell 2005, 17:205–214.
42. Li H, Durbin R: Fast and accurate long-read alignment with Burrows-Wheeler
transform. Bioinformatics 2010, 26:589–595.
43. Do CB, Batzoglou S: What is the expectation maximization algorithm?
Nat Biotechnol 2008, 26:897–899.
44. Ye K, Schulz MH, Long Q, Apweiler R, Ning Z: Pindel: a pattern growth
approach to detect break points of large deletions and medium sized
insertions from paired-end short reads. Bioinformatics 2009, 25:2865–2871.
45. Varela I, Tarpey P, Raine K, Huang D, Ong CK, Stephens P, Davies H, Jones D,
Lin ML, Teague J, Bignell G, Butler A, Cho J, Dalgliesh GL, Galappaththige D,
Greenman C, Hardy C, Jia M, Latimer C, Lau KW, Marshall J, McLaren S,
Menzies A, Mudie L, Stebbings L, Largaespada DA, Wessels LF, Richard S,
Kahnoski RJ, Anema J, et al: Exome sequencing identifies frequent
mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma.
Nature 2011, 469:539–542.
doi:10.1186/s13059-014-0455-6
Cite this article as: Chew et al.: Polygenic in vivo validation of cancer
mutations using transposons. Genome Biology 2014 15:455.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
